Transplantation Infection Clinical Trial
— TxL-FNOfficial title:
Renal Sensing of the Acidifying Effect of Sulphur-containing Amino Acids: Consequences for the Relation Between Protein Intake and Blood Pressure in Renal Transplant Recipients
Verified date | August 2017 |
Source | University Medical Center Groningen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Short-term (1-year) results of renal transplantation are now excellent (over 95%). Long-term (10-year and longer) results are, however, still disappointing. Where most research has focused on immunosuppression and infections, the investigators hypothesize that due to poor homeostatic capacity and necessary use of immunosuppressive and other drugs, renal transplant recipients are much more susceptible to poor dietary habits and exposure to potentially toxic contaminants than people of the general population, and that this contributes to accelerated function loss of the graft and excess risk of premature mortality, both contributing to poor long-term results. This study is a biobank and cohort study which investigates this hypothesis.
Status | Active, not recruiting |
Enrollment | 1007 |
Est. completion date | November 2028 |
Est. primary completion date | May 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: More than one year after transplantation, prognosis > 1 year, stable
outpatients situation - Exclusion Criteria: Acute illnesses, fever, current hospitalisation |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in renal function | Change in renal function over time | 20 years | |
Other | New Onset Diabetes After Transplantation | New Onset Diabetes | 20 years | |
Primary | Graft failure | Return to dialysis or re-transplantation | 20 years | |
Primary | All-cause mortality | Death | 20 years | |
Secondary | Cardiovascular mortality | Cause specific mortality | 20 years | |
Secondary | Cancer mortality | Cause specific mortality | 20 years | |
Secondary | Infectious disease mortality | Cause specific mortality | 20 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05047406 -
Bacillus Clausii in Liver Transplantation
|
Phase 2 | |
Completed |
NCT02463214 -
Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients
|
N/A | |
Recruiting |
NCT05198570 -
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
|
||
Completed |
NCT01808456 -
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
|
Phase 4 | |
Suspended |
NCT01301118 -
Graft Take and Microbiology in Burns
|
N/A | |
Completed |
NCT00610961 -
Induction Related BK Viremia in Renal Transplant Patients
|
Phase 4 | |
Recruiting |
NCT05215327 -
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
|
Phase 2 | |
Recruiting |
NCT05193058 -
Description of Lung Transplant Patients With Microbiologically Documented Stenotrophomonas Maltophilia Pneumonia and Impact of Treatment on Outcome
|
||
Unknown status |
NCT01983761 -
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT01471444 -
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
|
Phase 3 | |
Enrolling by invitation |
NCT01349738 -
Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants
|
N/A | |
Terminated |
NCT00473824 -
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
|
Phase 2 | |
Completed |
NCT00177801 -
Organ Transplant Infection Prevention and Detection Project
|
Phase 4 | |
Completed |
NCT01276457 -
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
|
Phase 3 | |
Completed |
NCT02328963 -
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
|
Phase 4 | |
Recruiting |
NCT04320303 -
CMV Infection and Immune Intervention After Transplantation
|
N/A | |
Active, not recruiting |
NCT01295645 -
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
|
Phase 2 | |
Completed |
NCT02329808 -
Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
|
||
Completed |
NCT01471067 -
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT04579471 -
Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study
|